Guidelines for standardized practice of sentinel lymph node biopsy in breast cancer (2022 abridged version)
-
摘要: 乳腺癌是女性最常见的恶性肿瘤,区域淋巴结状况作为重要的预后指标,可指导患者的淋巴结分期,并对后续治疗策略产生影响。前哨淋巴结活检术(sentinel lymph node biopsy,SLNB)标志着乳腺癌淋巴结外科处理进入微创时代,但其安全有效替代腋窝淋巴结清扫术应建立在规范化操作前提下。中国抗癌协会乳腺癌专业委员会组织业内专家依据循证医学方法制定《乳腺癌前哨淋巴结活检规范化操作指南》,内容涉及SLNB适应证、示踪剂选择与应用、组织标本处理、腋窝SLNB、新辅助治疗与SLNB、内乳SLNB。本指南将为乳腺癌相关医务工作者的临床实践提供有益指导和参考。Abstract: Breast cancer is the most common malignant tumor in women. Regional lymph node status is an important prognostic indicator that guides staging of tumors and influences application of adjuvant therapy. Minimally invasive lymph node surgery in breast cancer begins with sentinel lymph node biopsy (SLNB), which is established based on the premise of a standardized operation as a safe and effective replacement for axillary lymph node dissection. The Committee of Breast Cancer Society of China Anti-Cancer Association invited authoritative experts nationwide to participate in the preparation of the Guidelines for Standardized Practice of Sentinel Lymph Node Biopsy in Breast Cancer based on evidence-based medicine, which focuses on the indications for SLNB, tracer selection and application, tissue specimen processing, axillary SLNB, neoadjuvant therapy and SLNB, and internal mammary SLNB. The guideline aims to provide the most effective references for practitioners to achieve the best outcomes for patients with breast cancer.
-
Key words:
- breast cancer /
- sentinel lymph node biopsy (SLNB) /
- guideline
-
表 1 SLNB指征
适应证 禁忌证 豁免SLNB 早期浸润性乳腺癌 炎性乳腺癌 肿瘤完整切除并经石蜡组织病理充分评估为DCIS 性别不限 临床ALN阳性(cN+)并经穿刺证实 年龄≥70岁(合并疾病),cT1N0M0,HR阳性HER-2阴性,辅助治疗不受腋窝状态影响g cN0a cN+新辅助治疗后仍为阳性 cN0且影像学评估腋淋巴结阴性h 单灶或多中心性病变 cN2~3新辅助治疗后ycN0* − DCIS全乳切除术,或保乳术切除原发肿瘤后
影响SLNB成功率和准确性b− − cN0新辅助治疗后ycN0 − − 穿刺证实的cN1新辅助治疗后ycN0c − − 妊娠患者d − − 保乳术联合SLNB后同侧乳房复发/再发e − − ALN临床查体阴性但影像学1~2枚异常并
穿刺证实转移f− − a:临床查体和影像学检查可疑的ALN可通过超声引导下的细针穿刺或空芯针活检进行评估,细胞学或病理组织学阴性患者仍可进入SLNB流程;b:DCIS为穿刺组织病理或术中冰冻组织病理诊断;c:必须符合新辅助治疗前,穿刺阳性淋巴结放置标记夹并在术中检出/未置标记夹需采用核素+染料双示踪剂同时检出3枚及以上SLN;d:采用核素示踪剂的SLNB对胎儿的安全性已获得证实,因可能有过敏不推荐使用蓝染料示踪剂;e:保乳术联合SLNB(SLN阴性替代ALND)后同侧乳房复发/再发患者,再次(repeat,r)SLNB准确性和安全性已获得初步认可;f:综合2021版NCCN指南、2021版加拿大安大略及ASCO前哨淋巴结活检指南,依据中国专家意见本指南一般推荐;g:若不行SLNB,可豁免前哨不行ALN处理;h:前瞻性研究正在进行中,目前鼓励参加严格设计的临床试验;*:经新辅助治疗后临床ALN阴性 -
[1] Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe[J]. Surg Oncol, 1993, 2(6):335-339. [2] Qiu PF, Cong BB, Zhao RR, et al. Internal mammary sentinel lymph node biopsy with modified injection technique: high visualization rate and accurate staging[J]. Medicine (Baltimore), 2015, 94(41):e1790. [3] Van Loevezijn AA, Bartels SAL, van Duijnhoven FH, et al. Internal mammary chain sentinel nodes in early-stage breast cancer patients: Toward selective removal[J]. Ann Surg Oncol, 2019, 26(4):945-953. [4] Qiu PF, Zhao RR, Wang W, et al. Internal mammary sentinel lymph node biopsy in clinically axillary lymph node-positive breast cancer: diagnosis and implications for patient management[J]. Ann Surg Oncol, 2020, 27(2):375-383. [5] Ugras S, Matsen C, Eaton A, et al. Reoperative sentinel lymph node biopsy is feasible for locally recurrent breast cancer, but is it worthwhile[J]? Ann Surg Oncol, 2016;23(3): 744-748. [6] Poodt IGM, Vugts G, Maaskant-Braat AJG, et al. Risk of regional recurrence after negative repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence[J]. Ann Surg Oncol, 2018, 25(5):1312-1321. [7] Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10):1216-1235. [8] Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10):927-933. [9] Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393. [10] Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10):918-926. [11] Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12):1303-1310. [12] Muriel B, Fulvia GB, Francisco EP, et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline[J]. J Clin Oncol, 2021, 39(27):3056-3082. [13] 国家药典委员会. 中华人民共和国药典(2015年版二部)[M]. 北京: 化学工业出版社, 2015. [14] 王永胜,欧阳涛,王启堂,等.中国前哨淋巴结活检多中心协作研究 CBCSG-001最新资料报告[J].中华乳腺病杂志(电子版),2009,3(3). [15] Jiao D, Yang B, Chen J, et al. Efficacy and safety of mitoxantrone hydrochloride injection for tracing axillary sentinel nodes in breast cancer: a self-controlled clinical trial[J]. Front Oncol, 2022, 2:914057. [16] 叶京明,郭宝良,张建国,等.中国早期乳腺癌前哨淋巴结活检手术临床实践指南(2022版)[J].中国实用外科杂志,2022,42(2):137-145. [17] 杨耿侠,王磊,张英民,等.乳腺癌前哨淋巴结活检放射安全性研究[J].中华乳腺病杂志(电子版),2007,6:214-219. [18] Wang JW, Fan T, He YJ, et al. 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis[J]. Breast Cancer Res Treat, 2018, 168(2):365-370. [19] Wang C, Tong F, Cao Y, et al. Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer[J]. Breast Cancer Res Treat, 2021, 188(2):361-368. [20] Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis[J]. Am J Surg, 2020, 220(3):665-676. [21] Zhou P, Zheng W, Liu Y, et al. Preoperative contrast-enhanced ultrasound (CEUS) combined with 125I seeds localization in sentinel lymph node biopsy for breast cancer[J]. Cancer Manag Res, 2021, 24(13):1853-1860. [22] Li J, Chen X, Qi M, et al. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis[J]. PLoS One, 2018, 13(9):e0204364. [23] Sun X, Liu JJ, Wang YS, et al. Roles of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer patients[J]. Jpn J Clin Oncol, 2010, 40(8):722-725. [24] Shi F, Liang Z, Zhang Q, et al. The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis[J]. Breast, 2018, 39:39-45. [25] Sun X, Zhang Y, Wu S, et al. Intraoperative prediction of non- sentinel lymph node metastasis based on the molecular assay in breast cancer patients[J]. Cancer Manag Res, 2019, 11:9715-9723. [26] Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event[J]. JAMA Oncol, 2021, 7(12):1851-1855. [27] Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis[J]. Ann Surg, 2019, 269(3):432-442. [28] Qiu PF, Wang XE, Wang YS. Indications for individual internal mammary node irradiation[J]. Lancet Oncol, 2021, 22(2):e20. [29] 王永胜,赵荣荣,刘雁冰,等.精准医学时代乳腺癌内乳前哨淋巴结活检适应证的探讨[J].中华肿瘤杂志,2019,41(4):251-256.
点击查看大图
表(1)
计量
- 文章访问数: 1046
- HTML全文浏览量: 180
- PDF下载量: 366
- 被引次数: 0